India Immune-Oncology Drugs Market - Size, Share, Outlook, and Opportunity Analysis, 2018– 2026

India Immune-Oncology Drugs Market - Size, Share, Outlook, and Opportunity Analysis, 2018– 2026

Report Description

Immuno-Oncology refers to the use of body’s natural defenses to fight disease. It works by stimulating the immune system instead of fighting the tumors, avoiding disturbance in functionality of healthy cells. Immuno-oncology drugs facilitates long-term response against cancer by providing long-lasting memory to the immune system. Immuno-Oncology drugs works against a wide variety of cancers, which include non-small cell lung cancer, acute myeloid leukemia, lymphoma, multiple myeloma, breast cancer, and others. Immuno-oncology uses different types of cell-based immune therapies such as monoclonal antibodies, immune checkpoint inhibitors, cytokine-based immunotherapy, cancer vaccines, and other therapies. Commercially available immune-oncology therapies include Iplimumab, Nivolumab, Rituximab, Blinatumomab, Proleukin, Gardasil, and Kymriah.

Market Dynamics

Increasing prevalence of cancer in India is expected to drive India Immuno-Oncology Drugs market growth. For instance, according to National Cancer Registry Programme (NCRP), India, one woman dies of cervical cancer every 8 minutes in India. For every 2 women newly diagnosed with breast cancer, one woman dies of it in India. Furthermore, as many as 2,500 persons die every day due to tobacco-related diseases in India. Tobacco (smoked and smokeless) use accounted for around 317,928 deaths in men and women in 2018.

However, factors such as high-cost associated with immuno-oncology therapies makes it unaffordable for population in the low and middle-income class, to opt for these therapies, thus restraining growth of the market. For instance, Keytruda (Pembrolizumab), a monoclonal antibody for the treatment of various types of cancer costs around US$ 2,250 for a vial of 50 mg. Moreover, according to the World Health Organization (WHO), in February 2018, around 70% of deaths from cancer occur in low and middle-income countries. This can be attributed to high-prices of oncology therapies, which cannot be afforded by patients with low incomes.

Key features of the study:

• This report provides in-depth analysis of the India immuno-oncology drugs market, market size (US$ Mn), and Compound Annual Growth Rate (CAGR (%)) for the forecast period: 2018 – 2026, considering 2017 as the base year
• It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by leading players
• It profiles key players in the India immuno-oncology drugs market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
• Key players covered as a part of this study include Amgen, Inc., F. Hoffmann-La Roche AG, Intas Pharmaceuticals Ltd., AstraZeneca plc, Mylan N.V., Dr. Reddy's Laboratories, Bristol - Myers Squibb, Merck & Co., Inc., BIOCAD-Biotechnology company, Reliance Life Sciences, Biocon Limited and Hetero Drugs Limited.
• Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
• India immuno-oncology drugs market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for India immuno-oncology drugs market, research and consulting firms, new entrants, and financial analysts

Detailed Segmentation:

• India Immuno-Oncology Drugs Market, By Drug Type:
• Immune Checkpoint Inhibitors
• Nivolumab (Opdivo)
• Atezolimumab (Tecentriq)
• Pembrolizumab (Keytruda)
• Durvalumab (Imfinzi)
• Monoclonal Antibodies
• Rituximab (Rituxan)
• Trastazumab (Herceptin)
• Bevacizumab (Avastin)
• Nimotuzumab (Biomab EGFR)
• Pertuzumab (Perjeta)
• Ado-Trastuzumab Emtansine (Kadcyla)
• Cancer Vaccines
• Gardasil
• Cervarix
• India Immuno-Oncology Drugs Market, By Cancer Type:
• Lung Cancer
• Blood Cancer
• Breast Cancer
• Ovarian Cancer
• Cervical Cancer
• Colorectal Cancer
• Stomach Cancer
• Head & Neck Cancer
• Others
• Company Profiles
• Amgen, Inc.*
• Company Overview
• Product Portfolio
• Financial Performance
• Recent Highlights
• Strategies
• F. Hoffmann-La Roche AG
• Intas Pharmaceuticals Ltd.
• AstraZeneca plc
• Mylan N.V.
• Dr. Reddy's Laboratories
• Bristol - Myers Squibb
• Merck & Co., Inc.
• BIOCAD-Biotechnology company
• Reliance Life Sciences
• Biocon Limited
• Hetero Drugs Limited

“*” marked represents similar segmentation in other categories in the respective section.